Inventor · disambiguated record
William R. Roush
Also filed as: ROUSH WILLIAM · ROUSH WILLIAM R
42 granted patents·41 pending applications·398 citations·filing 1998–2024
97Inventor score
Files withIFM DUE INC25NOVARTIS AG22INNATE TUMOR IMMUNITY INC14SCRIPPS RESEARCH INST7MILLENNIUM PHARM INC5
Top patents by PatentIndex Score
83 records- 0198US6794516B2Synthesis of clasto-lactacystin β-lactone and analogs thereofMILLENNIUM PHARM INC·Filed 2003·Granted Sep 21, 2004·70 cites·23 claims
- 0298US6294560B1Synthesis of clasto-lactacystin β-lactone and analogs thereofMILLENNIUM PHARM INC·Filed 2000·Granted Sep 25, 2001·75 cites·6 claims
- 0397US6566553B2Synthesis of clasto-lactacystin β-lactone and analogs thereofMILLENNIUM PHARM INC·Filed 2001·Granted May 20, 2003·48 cites·2 claims
- 0496US6133308ASynthesis of clasto-lactacystin beta-lactone and analogs thereofMILLENNIUM PHARM INC·Filed 1998·Granted Oct 17, 2000·78 cites·34 claims
- 0594US6849743B2Synthesis of clasto-lactacystin β-lactone and analogs thereofMILLENNIUM PHARM INC·Filed 2003·Granted Feb 1, 2005·71 cites·2 claims
- 0693US10604542B2Cyclic dinucleotides for treating conditions associated with sting activity such as cancerINNATE TUMOR IMMUNITY INC·Filed 2017·Granted Mar 31, 2020·5 cites·30 claims
- 0793US10556903B2NLRP3 modulatorsINNATE TUMOR IMMUNITY INC·Filed 2017·Granted Feb 11, 2020·12 cites·5 claims
- 0892US10533005B2NLRP3 modulatorsINNATE TUMOR IMMUNITY INC·Filed 2018·Granted Jan 14, 2020·9 cites·41 claims
- 0990US11724992B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2021·Granted Aug 15, 2023·1 cites·20 claims
- 1089US10961270B2Compounds and compositions for treating conditions associated with sting activityINNATE TUMOR IMMUNITY INC·Filed 2020·Granted Mar 30, 2021·2 cites·7 claims
- 1187US11344543B2NLRP3 modulatorsINNATE TUMOR IMMUNITY INC·Filed 2018·Granted May 31, 2022·2 cites·25 claims
- 1287US10533007B2NLRP3 modulatorsInnate Tumor Immunity·Filed 2017·Granted Jan 14, 2020·10 cites·2 claims
- 1385US12351580B2NLRP3 modulatorsINNATE TUMOR IMMUNITY INC·Filed 2023·Granted Jul 8, 2025·0 cites·6 claims
- 1484US12084424B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2023·Granted Sep 10, 2024·0 cites·3 claims
- 1584US11370763B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2018·Granted Jun 28, 2022·1 cites·13 claims
- 1684US10654816B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS INFLAMMASOME RES INC·Filed 2019·Granted May 19, 2020·3 cites·19 claims
- 1783US12152018B2Compounds and compositions for treating conditions associated with STING activityIFM DUE INC·Filed 2022·Granted Nov 26, 2024·1 cites·36 claims
- 1881US11203579B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2018·Granted Dec 21, 2021·2 cites·19 claims
- 1978US11072612B2NLRP3 modulatorsINNATE TUMOR IMMUNITY INC·Filed 2019·Granted Jul 27, 2021·1 cites·5 claims
- 2077US2024391884A1Compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2175US10329303B2Heterocyclic inhibitors of monocarboxylate transporterSCRIPPS RESEARCH INST·Filed 2016·Granted Jun 25, 2019·2 cites·6 claims
- 2274US11760735B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2022·Granted Sep 19, 2023·0 cites·9 claims
- 2373US12171756B2NLRP3 modulatorsINNATE TUMOR IMMUNITY INC·Filed 2022·Granted Dec 24, 2024·0 cites·10 claims
- 2473US11827632B2NLRP3 modulatorsINNATE TUMOR IMMUNITY INC·Filed 2021·Granted Nov 28, 2023·0 cites·23 claims
- 2573US10851113B2Heterocyclic inhibitors of monocarboxylate transportersSCRIPPS RESEARCH INST·Filed 2019·Granted Dec 1, 2020·1 cites·18 claims
- 2671US11505571B2Compounds and compositions for treating conditions associated with sting activityINNATE TUMOR IMMUNITY INC·Filed 2021·Granted Nov 22, 2022·0 cites·7 claims
- 2770US11618749B2Compounds and compositions for treating conditions associated with STING activityIFM DUE INC·Filed 2019·Granted Apr 4, 2023·1 cites·12 claims
- 2870US2025136597A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2024·Application pending·0 cites
- 2967US10807944B2HDAC inhibitor compounds and methods of treatmentUNIV FLORIDA·Filed 2015·Granted Oct 20, 2020·1 cites·10 claims
- 3066US11560389B2Heterocyclic inhibitors of monocarboxylate transportersUNIV FLORIDA·Filed 2020·Granted Jan 24, 2023·0 cites·5 claims
- 3166US9493464B2Wee1 degradation inhibitorsSCRIPPS RESEARCH INST·Filed 2013·Granted Nov 15, 2016·2 cites·2 claims
- 3265US12421223B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2019·Granted Sep 23, 2025·0 cites·1 claims
- 3365US2024083895A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2023·Application pending·0 cites
- 3464US2020157096A1Nlrp3 modulatorsINNATE TUMOR IMMUNITY INC·Filed 2019·Application pending·0 cites
- 3563US11597706B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2017·Granted Mar 7, 2023·0 cites·2 claims
- 3662US2025084071A1Compounds and compositions for treating conditions associated with sting activityNOVARTIS PHARMA AG·Filed 2023·Application pending·0 cites
- 3761US11731934B2HDAC inhibitor compounds and methods of treatmentUNIV FLORIDA·Filed 2020·Granted Aug 22, 2023·0 cites·14 claims
- 3860US12503436B2Compounds and compositions for treating conditions associated with STING activityNOVARTIS PHARMA AG·Filed 2022·Granted Dec 23, 2025·0 cites·86 claims
- 3960US2023079631A1Compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2022·Application pending·0 cites
- 4059US2022024919A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2021·Application pending·0 cites
- 4158US10723756B2Cyclic dinucleotides for treating conditions associated with STING activity such as cancerINNATE TUMOR IMMUNITY INC·Filed 2017·Granted Jul 28, 2020·0 cites·2 claims
- 4258US2020163972A1Therapeutic Targeting of Casein Kinase 1 Delta in Breast CancerSCRIPPS RESEARCH INST·Filed 2019·Application pending·0 cites
- 4358US2023250060A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2023·Application pending·0 cites
- 4456US2024076285A1Compounds and compositions for treating conditions associated with sting activityVENKATRAMAN SHANKAR·Filed 2021·Application pending·0 cites
- 4554US11339136B2Compounds and compositions for treating conditions associated with NLRP activityNOVARTIS AG·Filed 2017·Granted May 24, 2022·0 cites·12 claims
- 4654US2024101556A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2022·Application pending·0 cites
- 4754US2024083879A1Oxalamide compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2022·Application pending·0 cites
- 4854US2024308978A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2022·Application pending·0 cites
- 4954US2022387397A1Compounds and compositions for treating conditions associated with nlrp activityNOVARTIS AG·Filed 2019·Application pending·0 cites
- 5053US2024051970A1Compounds and compositions for treating conditions associated with sting activityIFM DUE INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 83 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when William R. Roush files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →